Ro
About Ro
Recent News
Photon Just Killed the “E” In E-Prescribing
Here’s How Much Weight-Loss Drugs Wegovy, Zepbound and Foundayo Cost — and How to Pick the Best GLP-1 for You
FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide
How AI Helped 1 Man (and His Brother) Build a $1.8 Billion Company
The End of Incrementalism: Why Healthcare Innovation Is Finally Reshaping the Model
FemTech Mid 2026 : Future Landscape, IPO Pipeline, Capital Trends & AI Threats
The Peptide Boom Is Getting Out of Hand
Musely Secures $360M From General Catalyst without Giving up Equity
The Science Behind Social Media’s Peptide Obsession
New Bill Seeks to Lower Out-of-Pocket Drug Costs
Four Tatari Clients to Air Commercials During NBC’s Super Bowl LX Broadcast, Underscoring Its Role as the Go-To Partner for TV Advertising at Scale
Musely Secures $360 Million Non‑Dilutive Funding From General Catalyst’s Customer Value Fund